89BIO INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
89BIO INC. - More news...
89BIO INC. - More news...
- 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
- 89bio to Participate in the BofA Securities 2024 Health Care Conference
- 89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
- 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
- 89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
- 89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- 89bio to Participate in the Leerink Partners Global Biopharma Conference
- 89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- 89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- 89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- 89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
- 89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
- 89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
- 89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
- 89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
- 89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- 89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Announces U.S. FDA has Granted Breakthrough Therapy Designation for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)
- 89bio to Participate in the 2023 Cantor Global Healthcare Conference
- 89bio to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
- 89bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
- 89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- 89bio Publishes Positive Results from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) in Nature Medicine
- Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress
